Hutchmed (China) (HKG:0013) obtained conditional approval from China's National Medical Product Association for Tazemetostat as a treatment for patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutation who have received at least two systemic therapies.
Tazemetostat, sold under the brand name Tazverik, is a first-in-class methyltransferase inhibitor of EZH2. Іt is approved by the US FDA for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma, according to a Friday filing with the Hong Kong bourse.
The drugmaker's shares were down almost 3% in Monday's afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.